<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4601">
  <stage>Registered</stage>
  <submitdate>21/08/2014</submitdate>
  <approvaldate>21/08/2014</approvaldate>
  <nctid>NCT02228213</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis</studytitle>
    <scientifictitle>A Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple Sclerosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>U1111-1166-0910</secondaryid>
    <secondaryid>MIS416-202</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Secondary Progressive Multiple Sclerosis</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - MIS416
Treatment: drugs - Saline

Experimental: Treatment - 500 mcg MIS416 500 at 0.2 mg/mL administered i.v. once weekly for 52 weeks

Placebo Comparator: Saline - Saline administered i.v. once weekly for 52 weeks


Other interventions: MIS416
Intravenous administration weekly for 52 weeks

Treatment: drugs: Saline
Intravenous administration weekly for 52 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline of neuromuscular function at 12 months - Neuromuscular function will be assessed using the following test:
MS Function Composite (MSFC), comprising the; timed 25 Foot Walk, 9 Hole Peg Test (9HPT), and Paced Auditory Serial Addition Test (PASAT);
Jebsen Hand Function Test (JHFT);
Grip, tip and key pinch strength;
Symbol digit modalities test (SDMT);
Sloan low-contrast letter visual acuity (SLCVA);
6-minute walk test (6MWT);</outcome>
      <timepoint>Baseline, 3, 6, 9 and 12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Proportion of Participants with Serious and Non-Serious Adverse Events - Safety assessments will be conducted at each study visit and include; characterization of the type, incidence, severity, timing, seriousness, and relationship to treatment of adverse events (AEs); effects on vital signs and clinical laboratory parameters; changes on electrocardiograms (ECGs); and at 3 months and 12 months - the number of gadolinium-enhancing lesions on cranial MRI assessments.</outcome>
      <timepoint>Up to 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline of disability and health status at 12 months - Disability and health status will be assessed using the following assessments and patient reported outcomes:
Expanded Disability Status Scale (EDSS)
Patient Reported Outcomes (PROs) including;
SF-36 and its components;
MS Impact Scale (MSIS-29);
Neurological Fatigue Index for MS (NFI-MS);
Brief Pain Inventory (BPI).</outcome>
      <timepoint>Baseline, 3, 6, 9, and 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline of neurodegeneration by assessing changes in Magnetic Resonance Imaging (MRI) markers at 12 months - Disease activity and neurodegeneration will be assessing using Magnetic Resonance Imaging (MRI) markers including lesions, whole brain atrophy (WBA) and Magnetization Transfer Ratio (MTR).</outcome>
      <timepoint>Baseline, 3, and 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline of activity of immune biomarkers in serum - The effect on immune biomarkers will include the analysis of serum for some or all of the following markers: IP-10 (CXCL10), MCP-1 (CCL2), MIG (CXCL9), IL-8 (CXCL8), IFN?, Neopterin, IL-1RA, sTNF-R, IL-12/23, p40, CD62E (E-selectin), CD54 (ICAM-1), and CD106 (VCAM-1).</outcome>
      <timepoint>Up to 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline of activity of immune biomarkers in cerebrospinal fluid (CSF) - The effect on immune biomarkers will include the analysis of CSF for some or all of the following markers: IP-10 (CXCL10), MCP-1 (CCL2), MIG (CXCL9), IL-8 (CXCL8), IFN?, Neopterin, IL-1RA, sTNF-R, IL-12/23, p40, CD62E (E-selectin), CD54 (ICAM-1), and CD106 (VCAM-1).</outcome>
      <timepoint>Up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in Peripheral Blood Mononuclear Cell (PBMC) immune biomarkers - Some or all of these biomarkers may be assayed ex vivo: PBMC expression of mRNA encoding proteins involved in myeloid differentiation and immune regulatory function (e.g. VEGF, Arginine, INOS, IL-10, MMP9); PBMC myeloid subset production of IL-10, TGFß, IL-6, TNFa, IL-1ß, IFN?, IL-17, and GM-CSF in response to stimulation with LPS, LPS/IFN? or MIS416 ex vivo; and PBMC subset analysis of myeloid and dendritic cell subsets for immunoregulatory cell subset markers.</outcome>
      <timepoint>Up to 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. A historical or current cranial MRI scan demonstrating T2-hyperintense lesions
             consistent with MS.

          2. Has SPMS as determined by the 2010 Update to the McDonald Criteria

          3. An Expanded Disability Status Scale (EDSS) of 3.0 to 6.5 at Screening.

          4. Has SPMS which, in the judgment of the investigator, has been clinically active and
             functionally progressive within the 2 years prior to Screening

          5. The absence of MS relapse for at least two years prior to Baseline.

          6. Neurologically stable for at least four weeks prior to Screening.

          7. Has the following laboratory values within three days prior to initiation of
             Investigational Product:

               -  Absolute neutrophil count (ANC) &gt;= 1 x 109/L;

               -  Platelet count &gt;= 100 x 109/L;

               -  Serum creatinine =&lt; 1.5 mg/dL;

               -  Aspartate aminotransferase (AST) =&lt;2 × upper limit of normal;

               -  Alanine aminotransferase (ALT) =&lt; 2 × upper limit of normal.

          8. Provided written informed consent to participate.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Has primary Progressive MS (PPMS), Relapsing Remitting (RRMS), or progressive
             relapsing MS as determined by the 2010 update to the McDonald Criteria.

          2. Has not completed the discontinuation period for approved and/or investigational
             multiple sclerosis disease modifying therapies prior to screening.

          3. Has had any other immunomodulatory drug therapy or immunosuppressive therapy within
             four weeks prior to Screening, or systemic corticosteroids within the eight weeks
             prior to Screening.

          4. Any previous exposure to investigational MS therapeutic vaccines.

          5. Any use of cell-depleting monoclonal antibodies including, but not limited to,
             Rituximab, or Ocrelizumab.

          6. A diagnosis or history of collagen vascular disease (including Sjögren's syndrome and
             systemic lupus erythematosus), anticardiolipin antibody syndrome, cerebral autosomal
             dominant arteriopathy with subcortical infarcts and leukoencephalopathy, sarcoidosis,
             vasculitis, Behcet's syndrome and/or Lyme disease.

          7. Contraindication to MRI (e.g., pacemaker or other contraindicated implanted metal
             device, allergy to gadolinium, or unmanageable claustrophobia).

          8. A history of alcohol or drug abuse (including cannabinoid use) within two years prior
             to Screening.

          9. Has had major surgery or radiation therapy within four weeks prior to Screening.

         10. Has an active infection requiring antibiotics within two weeks prior to Screening.

         11. Has had active malignancy within two years of Screening, with the exception of basal
             cell carcinoma and squamous cell carcinoma of the skin.

         12. Uncontrolled congestive heart failure, myocardial infarction, cerebrovascular
             accident, coronary/peripheral artery bypass graft surgery, or transient ischemic
             attack within twelve weeks prior to Screening.

         13. Has angina, other symptomatic coronary artery disease, or known cardiomyopathy.

         14. Has symptomatic cardiac dysrhythmias requiring treatment, or persistent prolongation
             of the QTcF (Fredericia) interval to &gt; 450 msec for males or &gt; 470 msec for females.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>93</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA,VIC,WA</recruitmentstate>
    <hospital>The Wesley-St. Andrew's Research Institute - Brisbane</hospital>
    <hospital>PARC Clinical Research - Adelaide</hospital>
    <hospital>Nucleus Network - Centre for Clinical Studies - Melbourne</hospital>
    <hospital>Western Australian Neuroscience Research Institute - Perth</hospital>
    <hospital>Neurodegenerative Disorders Research - West Perth</hospital>
    <postcode>4066 - Brisbane</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>6009 - Perth</postcode>
    <postcode>6005 - West Perth</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Innate Immunotherapeutics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>INC Research</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether MIS416 administered once weekly over 12
      months is safe, tolerable, and improves a range of signs and symptoms associated with
      secondary progressive multiple sclerosis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02228213</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Michael Silverman</name>
      <address>Innate Immunotherapeutics</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>